Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31300122 | 0.77 | AKR1C3 (0.40) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4185086 | 0.76 | MEN1 (0.43) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL31300116 | 0.71 | GRM2 (0.38) | MAPTKDM4EHTTLMNA | |
| SCHEMBL18920701 | 0.71 | ALDH1A1 (0.36) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL32680462 | 0.68 | ALDH1A1 (0.36) | ALDH1A1MAPTKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL849461 | 0.64 | L3MBTL1 (0.57) | ALDH1A1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL16302281 | 0.63 | KMT2A (0.36) | ALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL11036457 | 0.61 | KEAP1 (0.40) | ALDH1A1MAPTKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL14860683 | 0.60 | CRBN (0.49) | ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL85673 | 0.56 | ALDH1A1 (0.50) | ALDH1A1MAPTKDM4EMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640497-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640497-B2 | Microbiocidal oxadiazole derivatives | PRF1, ARG1, ARG2 | ALDH1A1 467/4885MAPT 4785/4885KDM4E 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.